Skip to main content
    N

    Neurosense Therapeutics Ltd (NRSN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.69
    -0.07 (-3.98%)

    Market Cap: $3.21M

    Last updated: Nov 17, 2026 at 11:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    53%(9/17)
    Avg Surprise
    +12.67%
    Streak
    4 Q

    Upcoming Estimates

    Results pendingPeriod ending Jun 30, 2026
    EPS Consensus-$3.40
    Range-$3.40 - -$3.40
    1 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago-$0.80-325.0%
    60d ago$0.00n/a
    30d ago-$3.400.0%
    7d ago-$3.400.0%
    Current-$3.40
    Revenue Consensus
    N/A
    RangeN/A
    1 analysts
    Results pendingPeriod ending Sep 30, 2026
    EPS ConsensusN/A
    RangeN/A
    Revenue Consensus
    N/A
    RangeN/A
    1 analysts
    Last 12 of 25 reported quarters and 3 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    Exp. Mar 29
    --$3.67N/A--3--
    Sep 26EST
    Date TBD
    -N/AN/A-----
    Jun 26EST
    Date TBD
    --$3.40-$3.40 - -$3.40--1
    No revisions (30d)
    -
    Mar 26
    Reported Apr 6
    Not reported-$0.04N/A--1
    No revisions (30d)
    -
    Dec 25
    Reported Mar 25
    Not reported-$0.11N/A--1
    1
    0
    30d
    -
    Sep 25
    Reported Dec 17
    -$0.04-$0.06N/A+27.27%Beat1
    No revisions (30d)
    +63.6%
    Jun 25
    Reported Aug 1
    -$0.19-$0.23N/A+15.56%Beat0
    No revisions (30d)
    -850.0%
    Mar 25
    Reported Apr 7
    -$0.06-$0.15N/A+60.00%Beat0
    No revisions (30d)
    +82.9%
    Dec 24
    Reported Dec 31
    -$0.06-$0.15N/A+60.00%Beat0
    No revisions (30d)
    +62.5%
    Sep 24
    Reported Dec 18
    -$0.11-$0.11N/A0.00%In line0
    No revisions (30d)
    -210.0%
    Jun 24
    Reported Sep 30
    -$0.02-$0.18N/A+88.89%Beat1
    No revisions (30d)
    +95.5%
    Mar 24
    Reported Apr 5
    -$0.35-$0.20-$0.22 - -$0.19-75.00%Miss2
    No revisions (30d)
    -6.1%
    Dec 23
    Reported Mar 22
    -$0.16-$0.20-$0.20 - -$0.20+20.00%Beat1
    No revisions (30d)
    +40.7%
    Sep 23
    Reported Nov 28
    $0.10-$0.26-$0.26 - -$0.23+138.46%Beat2
    No revisions (30d)
    +140.0%
    Jun 23
    Reported Aug 16
    -$0.44-$0.28-$0.28 - -$0.28-57.14%Miss1
    No revisions (30d)
    -41.9%

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-2175.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio0.28xQuick Ratio0.28x
    Trading Statistics
    Beta1.72Avg Volume46.23K
    52-Week High$25.4052-Week Low$1.10

    Technical Indicators Dashboard

    As of Nov 16, 2026, the price is 59.2% below its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 31.4, in the neutral range between 30 and 70.

    Moving Averages

    SMA 10$1.63
    SMA 20$2.00
    SMA 50$4.14
    SMA 200$11.99
    EMA 10$1.81
    EMA 20$2.20
    EMA 50$4.06
    EMA 200$11.07

    MACD

    Line: -0.68Signal: -0.83Hist: 0.15

    ADX

    ADX: 28.3+DI: 11.0-DI: 16.3

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down64.0
    PSAR$1.34

    Bollinger Bands

    Upper Band$2.87
    Lower Band$1.13
    %B Position8683%(Upper)
    Band Width0.32

    RSI (14-Day)

    Neutral
    31.4

    Momentum Oscillators

    Stoch %K40.2
    Stoch %D44.0
    Williams %R-60.7
    ROC (10d)-15.1%
    Momentum-0.30
    CCI (20d)-55.2
    MFI (14d)29.9

    Volatility Measures

    ATR (14d)$0.66(39.3%)
    StdDev (20d)0.43
    Hist Vol168.0%(High)

    Volume Flow

    VWAP$1.69
    OBV3.5M
    AD Line38.0B
    CMF (20d)-0.143

    Volume Metrics

    Avg Vol (20d)49.8K
    Vol Ratio0.4x(Low)
    VWMA (20d)$1.80

    Pivot Points

    R3$1.92
    R2$1.87
    R1$1.82
    Pivot Point$1.77
    S1$1.72
    S2$1.67
    S3$1.62

    Advanced Oscillators

    TSI-44.55
    Ultimate Osc54.9
    KST-546.87

    Financial Performance

    Related GNG Research

    No research available

    Be the first to write about NRSN

    NRSN Valuation

    NRSN Profitability: Margins, ROIC and FCF

    Neurosense Therapeutics (NRSN) has an operating margin of 0.0% and a net margin of 0.0%.

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -2175.0%
    NRSN financial statements

    Neurosense Therapeutics Competitors

    The companies most similar to Neurosense Therapeutics (NRSN) include Senti Biosciences, CNS Pharmaceuticals and Reviva Pharmaceuticals Holdings.

    Sector: Healthcare

    NRSN Analyst Ratings

    Neurosense Therapeutics (NRSN) has a Buy consensus from 3 analysts: 2 Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell.

    Consensus
    Buy
    Analysts
    3
    Strong Buy
    0
    Buy
    2
    Hold
    1
    Sell
    0
    Strong Sell
    0

    NRSN Bull Case vs Bear Case

    Bull case

    • NRSN beat EPS estimates in 75.0% of its last 8 reported quarters.

    NRSN Earnings: Beat Rate

    The next report from Neurosense Therapeutics (NRSN) is expected on Mar 29, 2027.

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    24.6%

    NRSN Earnings Date

    NRSN reports Mar 29, 2027. The date is estimated.

    Updated Oct 27, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology

    Frequently Asked Questions About NRSN

    When does NRSN report earnings?

    Neurosense Therapeutics Ltd (NRSN) is expected to report earnings on Mar 29, 2027.

    Does NRSN pay dividends?

    Neurosense Therapeutics Ltd (NRSN) does not currently pay a regular dividend.

    What is NRSN's market cap?

    Neurosense Therapeutics Ltd (NRSN) has a market capitalization of $3.21M with a current stock price of $1.69.

    How do analysts rate NRSN stock?

    3 analysts cover Neurosense Therapeutics Ltd (NRSN): 0 rate it Strong Buy, 2 Buy, 1 Hold, 0 Sell and 0 Strong Sell, a consensus of Buy.

    NRSN pages: Overview, Financials

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.